MP13-Antiretroviral Resistances
Precision Medicine / IBS-MP13
The group coordinates the Spanish HIV Research Network Work Package on subtypes and resistance and contributes with several European organizations on HIV resistance (ESAR-SPREAD, Eurocord-CHAIN, EuRESIST-INTEGRATE) and hepatitis resistance (SHARED, HEPCARE). The group has been actively involved in recent research on Transmitted Drug Resistance in Spain and Europe, on genotypic investigation on HIV viral Tropism, on clinical significance of HIV low and very low-level viraemia, and on molecular epidemiology of HIV ti guide public helath interventions . The group is actively involved in hepatitis C virus research activities, coordinating several activities in GEHEP (Spanish Viral Hepatitis Study Group of the Clinical Microbiology & Infectious diseases Spanish Society), and coordinator of HEPCRESP, the Spanish national cohort on HCV resistance to new DAAs. The group is also in the Sterring Comittee of HEPCARE (Europe) and SHARED (Global) hepatitis
Research lines
- Elimination of hepatitis C
- Molecular epidemiology of HIV
- Microbiota and immunomodulation
- Microbiota and disease
- Microbiota and probiotics
- Antiretroviral Resistance
- Resistances in HCV
- Antibiotic resistance and alternative therapy
- smRNA and infection
Research networks
- RIS - Spanish Network for AIDS Research
- CIBERINFEC - Biomedical Research Network Center for Infectious Diseases
Keywords
HIV, Hepatitis C, Microbiota.
MARTA ILLESCAS LOPEZ
LUCIA CHAVES BLANCO
LUCIA PEREZ RODRIGUEZ
ANGELA ALCARAZ MARTINEZ
PALOMA MUÑOZ BAEZ
LAURA VIÑUELA GONZALEZ
RUBEN CEBRIAN CASTLE
ANGEL CARAZO GALICIAN
Mª DOLORES MERIDA DEL CANO
JOSE ANTONIO SANCHEZ ALVAREZ
MARTA ALVAREZ ESTEVEZ
NATALIA CHUECA PORCUNA
ADOLFO DE SALAZAR GONZALEZ
ANA SOURCES LOPEZ
FEDERICO GARCIA GARCIA
FERNANDO GARCIA GARCIA
JOSEFA LOPEZ BUENO
Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer
ANTIOXIDANTS, 2023;
FI: 7; Q1
Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023;
FI: 8,4; Q1
Human adipose tissue as a major reservoir of cytomegalovirus-reactive T cells
FRONTIERS IN IMMUNOLOGY, 2023;
FI: 7,3; Q1
Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study
ANTIBIOTICS-BASEL, 2023;
FI: 4,8; Q2
Monkeypox Virus Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023;
FI: 1,5; Q4
ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
CLINICAL MICROBIOLOGY AND INFECTION, 2022;
FI: 13,31; D1
In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant
TRANSBOUNDARY AND EMERGING DISEASES, 2022;
FI: 4,521; D1
Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic
TRANSBOUNDARY AND EMERGING DISEASES, 2022;
FI: 4,521; D1
Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe
Journal of Hepatology, 2022;
FI: 30,083; D1
Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV
CLINICAL MICROBIOLOGY AND INFECTION, 2022;
FI: 13,31; D1
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
JOURNAL OF CLINICAL RESEARCH, 2021;
FI: 14,808; D1
Allium-Derived Compound Propyl Propane Thiosulfonate (PTSO) Attenuates Metabolic Alterations in Mice Fed a High-Fat Diet through Its Anti-Inflammatory and Prebiotic Properties.
NUTRIENTS, 2021;
FI: 5,719; Q1
Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-Resistant Staphylococcus aureus.
ANTIBIOTICS-BASEL, 2021;
FI: 4,639; Q2
Antibody response in patients admitted to the hospital with suspected SARS-CoV-2 infection: results from a multicenter study across Spain
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;
FI: 3,267; Q3
Comparison between Aptima (R) assays (Hologic) and the CoBAS (R) 6800 system (Roche) for the diagnosis of sexually transmitted infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2021;
FI: 3,267; Q3
A Multi-Omics Approach Reveals New Signatures in Obese Allergic Asthmatic Children
BIOMEDICINE, 2020;
FI: 4,717; Q1
Extracellular Protease ADAMTS1 Is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells
CANCER, 2020;
FI: 6,126; Q1
Detection of sexually transmitted disease-causing pathogens from direct clinical specimens with the multiplex PCR-based STD Direct Flow Chip Kit
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2020;
FI: 2,837; Q2
Bacteria associated with periodontal disease are also increased in health
ORAL MEDICINE ORAL PATHOLOGY AND ORAL SURGERY, 2020;
FI: 1,596; Q3
Current position of viral load versus hepatitis C core antigen testing
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY, 2020;
FI: 1,654; Q4
Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programs
Journal of Hepatology, 2019;
FI: 18,946; D1
Surveillance of transmitted drug resistance to integrate inhibitors in Spain: implications for clinical practice
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;
FI: 5,113; D1
High efficacy of resistance-guided treatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, 2019;
FI: 18,946; D1
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Journal of Hepatology, 2019;
FI: 18,946; D1
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;
FI: 5,113; D1
Continued spread of the CRF19_cpx variant among HIV-positive MSM patients in Spain
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018;
FI: 5,217; D1
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 (vol 37, pg 17, 2018)
DRUG RESISTANCE UPDATES, 2018;
FI: 11,63; D1
Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018;
FI: 10,231; D1
Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution
BRITISH JOURNAL OF PHARMACOLOGY, 2018;
FI: 6,81; D1
Relapse or reinfection after failing hepatitis C direct acting antiviral treatment: Unraveled by phylogenetic analysis
PLOSONE, 2018;
FI: 2,766; Q1
Morphological and immunophenotypical differences between chronic periodontitis and peri-implantitis - a cross-sectional study
EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2017;
FI: 3,567; D1
Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition.
MOLECULAR NUTRITION & FOOD RESEARCH, 2017;
FI: 4,323; D1
Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study)
JOURNAL OF VIRAL HEPATITIS, 2017;
FI: 4,122; Q1
High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach
PLOSONE, 2017;
FI: 2,806; Q1
Contribution of Oxidative Stress to Non-AIDS Events in HIV-Infected Patients
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017;
FI: 3,935; Q1
Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE)
JOURNAL OF INFECTIOUS DISEASES, 2016;
FI: 6,344; D1
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI: 4,919; D1
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI: 4,919; D1
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016;
FI: 4,919; D1
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
CLINICAL INFECTIOUS DISEASES, 2016;
FI: 8,736; D1
Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)
Clin Microbiol Infect, 2015;
FI: 5,768; D1
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naïve adults
Clin Microbiol Infect, 2015;
FI: 5,768; D1
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;
FI: 5,313; D1
Primary resistance to integrate strand-transfer inhibitors in Europe
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015;
FI: 5,313; D1
Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
JOURNAL OF INFECTION, 2015;
FI: 4,441; Q1
Molecular epidemiological surveillance of Hepatitis Delta virus infection
Funder: SPANISH SOCIETY OF INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY
File number: GEHEP-2023-AFL
Execution time: 01/01/2024 - 31/12/2024
IP: ANA FUENTES LOPEZ
INFLUENCE OF INTESTINAL MICROBIOTA ON THE SEVERITY OF ACUTE PANCREATITIS (MIGPA)
Funder: UNIVERSITY OF GRANADA
File number: C-CTS-311-UGR23
Execution time: 01/01/2024 - 31/12/2025
PI: NATALIA CHUECA PORCUNA
Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network RELECOV 2.0
Funder: EUROPEAN COMMISSION
File number: RELECOV 2022
Execution time: 01/07/2023 - 30/06/2025
PI: FEDERICO GARCIA GARCIA
Epidemiological surveillance of the transmission of resistance to antiretrovirals in Spain. Implementation of a real-time transmission cluster study strategy.
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI22 / 00882
Execution time: 01/01/2023 - 31/12/2025
PI: FEDERICO GARCIA GARCIA
RELECOV 2.0 – Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network
Funder: EUROPEAN COMMISSION
File number: RELECOV 2022
Execution time: 01/03/2023 - 01/07/2024
PI: FEDERICO GARCIA GARCIA
Development of a commercial kit for massive sequencing of micro RNA, based on an innovative technology with reduced biases (Double Tailing Trap)
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: DTS22 / 00151
Execution time: 01/01/2023 - 31/12/2025
IP: ANGEL CARAZO GALLEGO
Characterization of the antibody response to the anti-COVID-19 BNT162b2 vaccine and its determinants
Funder: COUNCIL OF HEALTH AND FAMILIES
File number: PI-0198-2021
Execution time: 10/12/2021 - 09/12/2024
PI: FEDERICO GARCIA GARCIA
Enhancing Whole Genome Sequencing (WGS) and/or ReverseTranscription Polymerase Chain Reaction (RT-PCR) national infrastructures and capacities to respond to the Covid-19 pandemic in Spain.
Funder: EUROPEAN COMMISSION
File number: HERA INCUBATOR 2021
Execution time: 03/09/2021 - 02/10/2022
PI: FEDERICO GARCIA GARCIA
CB21/13/00088 FEDERICO GARCÍA GARCÍA THEMATIC AREA: INFECTIOUS DISEASES
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: CB21 / 13/00088
Execution time: 01/01/2022 - 31/12/2025
PI: FEDERICO GARCIA GARCIA
Hepatitis C Microelimination Program in a social integration center.
Funder: GILEAD SCIENCES EUROPE LTD
File number: GILEAD2021-FGG
Execution time: 02/05/2022 - 01/05/2024
PI: FEDERICO GARCIA GARCIA
Towards the elimination of hepatitis C in patients with Serious Mental Disorder
Funder: SPANISH SOCIETY OF INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY
File number: GEHEP-2020 / FGG
Execution time: 31/12/2020 - 31/12/2021
PI: FEDERICO GARCIA GARCIA
Clinical Relevance and Economic Impact of the Correct Assignment of the Genotype / Subtype of Hepatitis C Virus in the Age of Direct-Acting Antivirals
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
File number: PI-0411-2014
Execution time: 31/07/2015 - 30/09/2017
IP: MARTA ALVAREZ ESTEVEZ
Virological characterization of patients who do not achieve Sustained Viral Response to treatment with direct-acting antivirals against the hepatitis C virus in interferon-free regimens.
Funder: SPANISH SOCIETY OF INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY
File number: GEHEP-004-FGG
Execution time: 04/07/2017 - 03/07/2018
PI: FEDERICO GARCIA GARCIA
Virological characterization of patients who do not achieve Sustained Viral Response to treatment with Direct-acting Antivirals against Hepatitis C Virus
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI15 / 00713
Execution time: 01/01/2016 - 31/12/2018
PI: FEDERICO GARCIA GARCIA
Implementation of a Web Application for Real-Time Monitoring and Characterization of Clusters With High HIV Transmission Rate in Eastern Andalusia
Funder: COUNCIL OF HEALTH
File number: PI-0550-2017
Execution time: 01/01/2018 - 31/12/2020
IP: MARTA ALVAREZ ESTEVEZ
RD16 / 0025/0040 - AIDS NETWORK- FEDERICO GARCÍA GARCÍA
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: RD16 / 0025/0040
Execution time: 01/01/2017 - 31/12/2021
PI: FEDERICO GARCIA GARCIA
EPIDEMIOLOGICAL SURVEILLANCE OF PRIMARY AND TRANSMITTED RESISTANCE TO ANTIRETROVIRALS IN SPAIN. PHILOGENETIC, PHILODYNAMIC AND PHILOETHNICAL STUDY
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI18 / 00819
Execution time: 01/01/2019 - 31/12/2021
PI: FEDERICO GARCIA GARCIA
CDC- Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study.
Financing: FOUNDATION FOR BIOMEDICAL RESEARCH OF LA PAZ UNIVERSITY HOSPITAL
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 31/08/2021 - 31/08/2025
PI: FEDERICO GARCIA GARCIA
National mapping on carbapenemases in Spain. The CARBA-MAP study
Funder: MERCK SHARP & DOHME DE ESPAÑA SA
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 15/10/2020 - 30/09/2021
PI: NATALIA CHUECA PORCUNA
Effectiveness of doxycycline in the negativization of viral replication in COVID-19. Randomized Phase II clinical trial.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 04/12/2020 - 31/12/2021
PI: NATALIA CHUECA PORCUNA